While that may seem recent, the decade of research, multiple years of clinical trials, and the prior approval of tirzepatide as Mounjaro in 2022 provide a sturdy foundation of evidence for its use
- Tirzepatide versus Semaglutide Once Weekly in a Type 2 Diabetes Study (SURPASS-2, NEJM 2021) Semaglutide Prescribing Information Reference (FDA, 2025) Tirzepatide Prescribing Information Reference (FDA, 2025) What Real Users Say When the Drug Choice Turns Into Daily Life The Comparison Starts With the Drug
Keep an eye on your messages to avoid delays in your assessment
Discussion of potential risks and benefits: Understanding what to expect during and after the transition
Recalls & Warnings July 21, 2003 FTC Stops False Advertising of Heavily Promoted Supplements for Breast Enhancment, Male Virility, and Snoring On June 10, 2003, the Federal Trade Commission (FTC) announced that infomercial marketers Wellquest International, Inc
doi: 10.1210/me.2003-0048 113 BarthelTKMathernDRWhitfieldGKHausslerCAHopperHATHsiehJCet al
